Analysis of local recurrence pattern for limited stage small cell lung cancer after IMRT plus chemotherapy
Yan Wenbin, Liu Xuan, Zhou Zongmei, Wang Yuxia, Xiao Zefen, Feng Qinfu, Chen Dongfu, LüJima, Liang Jun, Deng Lei, Zhang Tao, Wang Wenqing, BI Nan, Wang Xin, wang xiaozhen, Hui Zhouguang, Wang Luhua
Department of Radiation Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College , Beijing 100021,China
Abstract：Objective To investigate localized regional recurrence after chemotherapy and chest radiotherapy in limited stage small cell lung cancer (LS-SCLC),and explore the relationship between recurrence location and radiotherapy and chemotherapy and its influencing factors.Methods From 2006 to 2014,pathological LS-SCLC treated in CAMS,125 patients had local recurrence,Kaplan-Meier statistical method was used to analyze the survival rate and PFS of each recurrence site. Log-rank was used to compare the survival rate of each group. Univariate analysis includes Chi-squareand t-test for the factors for the recurrence site. Multivariate analysis using Logistic regression.Results The 1-,2-and 5-year overall survival rates were 92.0%,46.4% and 14.7%,respectively. The median progression time was 12.96 months,The median survival time after progression was 11.5 months,and the 1-,2-,and 5-year overall survival rates were 45.0%,23.0%,and 10.0%,respectively. The recurrence sites include intrapulmonary recurrence (67 patients),regional lymph nodes (21 patients),simultaneous intrapulmonary and regional lymph nodes (28 patients), and contralateral or supraclavicular lymph nodes (9 patients). The median survival time were 23.96 months,24.76 months,23.23 months,and 18.66 months,and the 2-year survival rates were 49%,52%,46%,and11%,respectively (P=0.000,0.004,0.008). In 6 patients (4.0%),5 patients were located in the supraclavicular region,and 1 patient (0.8%) in the field.Conclusions For LS-SCLC undergoing IMRT and chemotherapy,the local failure location is mainly located in the pulmonary,and further treatment of the split dose and targets requires further clinical exploration.
Yan Wenbin,Liu Xuan,Zhou Zongmei et al. Analysis of local recurrence pattern for limited stage small cell lung cancer after IMRT plus chemotherapy[J]. Chinese Journal of Radiation Oncology, 2020, 29(3): 175-178.
[1] Amini A,Byers LA,Welsh JW,et al. Progress in the management of limited-stage small cell lung cancer[J]. Cancer,2014,120(6):790-798. DOI:10.1002/cncr.28505.
[2] De Ruysscher D,Bremer RH,Koppe F,et al. Omission of elective node irradiation on basis of CT-scans in patients with limited disease small cell lung cancer:a phase Ⅱ trial[J]. Radiother Oncol,2006,80(3):307-312. DOI:10.1016/j.radonc.2006.07.029.
[3] van Loon J,De Ruysscher D,Wanders R,et al. Selective nodal irradiation on basis of (18) FDG-PET scans in limited-disease small-cell lung cancer:a prospective study[J]. Int J Radiat Oncol Biol Phys,2010,77(2):329-336. DOI:10.1016/j.ijrobp.2009.04.075.
[4] Hu X,Bao Y,Zhang L,et al. Omitting elective nodal irradiation and irradiating postinduction versus preinduction chemotherapy tumor extent for limited-stage small cell lung cancer:interim analysis of a prospective randomized noninferiority trial[J]. Cancer,2012,118(1):278-287. DOI:10.1002/cncr.26119.
[5] Valan CD,Slagsvold JE,Halvorsen TO,et al. Survival in limited disease small cell lung cancer according to N3lymph node involvement[J]. Anticancer Res,2018,38(2):871-876. DOI:10.21873/anticanres.12296.
[6] Kim HJ,Choi CM,Kim SG. The younger patients have more better prognosis in limited disease small cell lung cancer[J]. Tuberc Respir Dis,2016,79(4):274-281. DOI:10.4046/trd.2016.79.4.274.
[7] Stinchcombe TE,Fan W,Schild SE,et al. A pooled analysis of individual patient data from National Clinical Trials Network clinical trials of concurrent chemoradiotherapy for limited-stage small cell lung cancer in elderly patients versus younger patients[J]. Cancer,2019,125(3):382-390. DOI:10.1002/cncr.31813.
[8] Turrisi AT,3rd,Kim K,Blum R,et al. Twice-daily compared with once-daily thoracic radiotherapy in limited small-cell lung cancer treated concurrently with cisplatin and etoposide[J]. N Engl J Med,1999,340(4):265-271. DOI:10.1056/nejm199901283400403.
[9] De Ruysscher D,Lueza B,Le Pechoux C,et al. Impact of thoracic radiotherapy timing in limited-stage small-cell lung cancer:usefulness of the individual patient data meta-analysis[J]. Ann Oncol,2016,27(10):1818-1828. DOI:10.1093/annonc/mdw263.
[10] Zhao S,Zhou T,Ma S,et al. Effects of thoracic radiotherapy timing and duration on progression-free survival in limited-stage small cell lung cancer[J]. Cancer Med,2018,7(9):4208-4216. DOI:10.1002/cam4.1616.
[11] Zhu L,Zhang S,Xu X,et al. Increased biological effective dose of radiation correlates with prolonged survival of patients with limited-stage small cell lung cancer:asystematic review[J/OL]. PLoS One,2016,11(5):e0156494. DOI:10.1371/journal.pone.0156494.
[12] Zahra A,Chang T,Hejleh TA,et al. Once daily high-dose radiation (>/=60 Gy) treatment in limited stage small cell lung cancer[J]. J Oncol Transl Res,2016,2(1):108-124. DOI:10.4172/2476-2261.1000108.
[13] Faivre-Finn C,Snee M,Ashcroft L,et al. Concurrent once-daily versus twice-daily chemoradiotherapy in patients with limited-stage small-cell lung cancer (CONVERT):an open-label,phase 3,randomised,superiority trial[J]. Lancet Oncol,2017,18(8):1116-1125. DOI:10.1016/s1470-2045(17)30318-2.
2020, Vol. 29 
